- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Late-onset lysosomal acid lipase deficiency (LAL-D)
- Meeting Date: July 2026
Sebelipase alfa – July 2026
- Solution for injection 20 mg in 10 mL vial
Public Summary Documents
Last updated
13 November 2026
